TWI879756B - 抗ｔｒｅｍ２抗體及其使用方法 - Google Patents

抗ｔｒｅｍ２抗體及其使用方法 Download PDF

Info

Publication number
TWI879756B
TWI879756B TW109105560A TW109105560A TWI879756B TW I879756 B TWI879756 B TW I879756B TW 109105560 A TW109105560 A TW 109105560A TW 109105560 A TW109105560 A TW 109105560A TW I879756 B TWI879756 B TW I879756B
Authority
TW
Taiwan
Prior art keywords
seq
sequence
amino acid
cdr
trem2
Prior art date
Application number
TW109105560A
Other languages
English (en)
Chinese (zh)
Other versions
TW202045543A (zh
Inventor
馬克 S 丹尼斯
雪莉 鄧肯
凱瑟琳 里辛哥
凱瑟琳 Ｍ 夢露
約書亞 Ｉ 朴
瑞秋 普洛洛可
菊 施
安基塔 斯里瓦斯塔娃
倫格里希 貝汀娜 凡
賴利 沃許
Original Assignee
美商戴納立製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商戴納立製藥公司 filed Critical 美商戴納立製藥公司
Publication of TW202045543A publication Critical patent/TW202045543A/zh
Application granted granted Critical
Publication of TWI879756B publication Critical patent/TWI879756B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW109105560A 2019-02-20 2020-02-20 抗ｔｒｅｍ２抗體及其使用方法 TWI879756B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962808141P 2019-02-20 2019-02-20
US62/808,141 2019-02-20

Publications (2)

Publication Number Publication Date
TW202045543A TW202045543A (zh) 2020-12-16
TWI879756B true TWI879756B (zh) 2025-04-11

Family

ID=69844940

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109105560A TWI879756B (zh) 2019-02-20 2020-02-20 抗ｔｒｅｍ２抗體及其使用方法

Country Status (21)

Country Link
US (2) US20220073609A1 (enExample)
EP (1) EP3927743A1 (enExample)
JP (2) JP7543290B2 (enExample)
KR (1) KR20210135518A (enExample)
CN (1) CN113614110B (enExample)
AR (1) AR118144A1 (enExample)
AU (1) AU2020226754A1 (enExample)
BR (1) BR112021015656A2 (enExample)
CA (1) CA3130086A1 (enExample)
CL (1) CL2021002206A1 (enExample)
CO (1) CO2021012230A2 (enExample)
EA (1) EA202192294A1 (enExample)
EC (1) ECSP21069105A (enExample)
IL (1) IL285651A (enExample)
MA (1) MA55025A (enExample)
MX (1) MX2021009722A (enExample)
PE (1) PE20211979A1 (enExample)
PH (1) PH12021552002A1 (enExample)
SG (1) SG11202108734VA (enExample)
TW (1) TWI879756B (enExample)
WO (2) WO2020172457A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
EP3902836A4 (en) * 2018-12-18 2022-08-31 Boehringer Ingelheim IO Canada Inc. FLT3 AGONISTIC ANTIBODIES AND THEIR USES
PE20211979A1 (es) 2019-02-20 2021-10-05 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
EP4337317A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Agonists of trem2
CN118765204A (zh) 2022-02-23 2024-10-11 艾利妥 抗trem2抗体的使用方法
WO2023192288A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
WO2024160736A1 (en) 2023-01-30 2024-08-08 Isar Bioscience Gmbh Human anti-trem2 antibody for treating neurodegenerative disorders
WO2025032071A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025106361A1 (en) * 2023-11-15 2025-05-22 Merck Sharp & Dohme Llc Human nectin-4 binders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023019A2 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
WO2017062672A2 (en) * 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
CA2746470A1 (en) 2009-01-06 2010-07-15 Raymond-David Pridmore Processing of macronutrients
EP2810652A3 (en) 2009-03-05 2015-03-11 AbbVie Inc. IL-17 binding proteins
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
JPWO2012176779A1 (ja) * 2011-06-20 2015-02-23 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
EP2992013B1 (en) 2013-04-29 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
EP3041865A2 (en) 2013-09-03 2016-07-13 NovImmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
CN105218669A (zh) 2014-06-10 2016-01-06 河北翰林生物科技有限公司 制备抗人r47h-trem2突变体的人单克隆抗体的方法
KR102506663B1 (ko) 2014-09-28 2023-03-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
EP3277305B1 (en) 2015-03-31 2021-07-21 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
US11066456B2 (en) 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
US11326182B2 (en) 2016-04-29 2022-05-10 Voyager Therapeutics, Inc. Compositions for the treatment of disease
AU2017300040A1 (en) 2016-07-22 2019-01-24 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) TREM2 cleavage modulators and uses thereof
EP3559043A4 (en) 2016-12-23 2020-08-05 Bluefin Biomedicine, Inc. ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
US20190367623A1 (en) 2017-01-17 2019-12-05 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
PL3583120T3 (pl) 2017-02-17 2023-01-09 Denali Therapeutics Inc. Konstruowane polipeptydy wiążące receptory transferyny
MA47499A (fr) 2017-02-17 2019-12-25 Denali Therapeutics Inc Anticorps anti-tau et leurs procédés d'utilisation
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
AU2018307877A1 (en) 2017-07-27 2020-01-02 Novartis Ag Sheddase resistant TREM2 variants
CA3061755A1 (en) 2017-08-03 2019-02-07 Alector Llc Anti-trem2 antibodies and methods of use thereof
PT3665192T (pt) 2017-08-10 2023-09-25 Denali Therapeutics Inc Polipeptídeos de ligação ao recetor de transferrina manipulados
CA3075285A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
WO2019070577A1 (en) 2017-10-02 2019-04-11 Denali Therapeutics Inc. FUSION PROTEINS COMPRISING SUBSTITUTE ENZYM THERAPY ENZYMES
US20210186917A1 (en) 2017-10-17 2021-06-24 The Translational Genomics Research Institute Trem2 agonists for the stimulation of microglia and methods of identification
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
AU2019207735A1 (en) 2018-01-10 2020-07-23 Denali Therapeutics Inc. Transferrin receptor-binding polypeptides and uses thereof
US20210284702A1 (en) 2018-06-18 2021-09-16 Denali Therapeutics Inc. Fusion proteins comprising progranulin
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
CN112839955A (zh) 2018-08-16 2021-05-25 戴纳立制药公司 经工程改造双特异性蛋白
SG11202101436SA (en) 2018-08-22 2021-03-30 Denali Therapeutics Inc Anti-her2 polypeptides and methods of use thereof
CA3111569A1 (en) 2018-09-11 2020-03-19 Washington University Anti-trem-2 agonist antibodies
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102156165B1 (ko) 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
WO2020112889A2 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
CA3121927A1 (en) 2018-12-10 2020-06-18 Denali Therapeutics Inc. Lysosomal storage disorder biomarkers and methods of use thereof
CA3122725A1 (en) 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
KR20210104079A (ko) 2018-12-11 2021-08-24 파이오니어 임뮤노테라퓨틱스, 인코퍼레이티드 항-trem2 항체를 사용하는 방법
PE20211979A1 (es) 2019-02-20 2021-10-05 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
BR112021019520A2 (pt) 2019-04-03 2021-12-07 Denali Therapeutics Inc Composição farmacêutica, método para tratar a síndrome de hunter e uso de uma composição farmacêutica
CN114981297A (zh) 2019-12-23 2022-08-30 戴纳立制药公司 颗粒蛋白前体变体
WO2021146256A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
JP2023512450A (ja) 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
WO2021158986A1 (en) 2020-02-07 2021-08-12 Denali Therapeutics Inc. Methods for the treatment of hunter syndrome
AR121384A1 (es) 2020-02-19 2022-06-01 Denali Therapeutics Inc Proteínas biespecíficas anti-her2 diseñadas por ingeniería genética
MA71661A (fr) 2020-10-14 2025-05-30 Denali Therapeutics Inc. Protéines de fusion comprenant des enzymes sulfoglucosamine sulfohydrolase et méthodes associées

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016023019A2 (en) * 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
WO2017062672A2 (en) * 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 Lang-Yue Hu et al., Triggering receptor expressed on myeloid cells 2 (TREM2) dependent microglial activation promotes cisplatin-induced peripheral neuropathy in mice. Brain Behav Immun. 68: doi: 10.1016/j.bbi.2017.10.011. 2018 Feb: Epub 2017 Oct 16. 132-145. *

Also Published As

Publication number Publication date
CN113614110B (zh) 2025-03-25
JP7543290B2 (ja) 2024-09-02
CN113614110A (zh) 2021-11-05
EP3927743A1 (en) 2021-12-29
ECSP21069105A (es) 2021-11-18
JP2022520868A (ja) 2022-04-01
PH12021552002A1 (en) 2022-09-19
US12240902B2 (en) 2025-03-04
WO2020172457A1 (en) 2020-08-27
JP2024164116A (ja) 2024-11-26
EA202192294A1 (ru) 2021-12-24
TW202045543A (zh) 2020-12-16
PE20211979A1 (es) 2021-10-05
US20220073609A1 (en) 2022-03-10
SG11202108734VA (en) 2021-09-29
US20220119522A1 (en) 2022-04-21
MA55025A (fr) 2021-12-29
BR112021015656A2 (pt) 2021-10-05
CL2021002206A1 (es) 2022-04-22
MX2021009722A (es) 2021-09-14
KR20210135518A (ko) 2021-11-15
WO2020172450A1 (en) 2020-08-27
IL285651A (en) 2021-09-30
CO2021012230A2 (es) 2021-09-30
AR118144A1 (es) 2021-09-22
AU2020226754A1 (en) 2021-09-16
CA3130086A1 (en) 2020-08-27

Similar Documents

Publication Publication Date Title
TWI879756B (zh) 抗ｔｒｅｍ２抗體及其使用方法
US11124567B2 (en) Anti-TREM2 antibodies and methods of use thereof
JP7403441B2 (ja) 抗ｔｒｅｍ２抗体及びその使用方法
JP6290212B2 (ja) タウオパチーの処置方法
TWI890727B (zh) 抗trem2 抗體及其使用方法
TW201827466A (zh) 抗-ｔａｕ抗體及使用方法
JP2016525502A (ja) タウオパチーの処置方法
KR20240133705A (ko) 항-pilra 항체, 이의 용도, 및 관련 방법 및 시약
EA049305B1 (ru) Антитела к trem2 и способы их применения
HK40063035A (en) Anti-trem2 antibodies and methods of use thereof
HK40082564A (en) Anti-trem2 antibodies and methods of use thereof
US20250215077A1 (en) Monovalent anti-trem2 binding molecules and methods of use thereof
TW202515915A (zh) 抗ｐｉｌｒａ抗體、其用途以及相關方法及試劑